These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38267844)

  • 1. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
    Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
    BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of complicated infective endocarditis due to Enterococcus faecium in a patient with substance use disorder using oritavancin as sequential maintenance therapy.
    Giuliano G; Benedetti S; Sambo M; Pierguidi F; Tumbarello M
    Clin Microbiol Infect; 2024 Apr; 30(4):556-557. PubMed ID: 38253314
    [No Abstract]   [Full Text] [Related]  

  • 3. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
    Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
    J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
    Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
    Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
    Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
    Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
    PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
    Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
    Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
    Chastain DB; Davis A
    Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment.
    Di Cecco C; Monticelli J; Di Bella S; Di Maso V; Luzzati R
    J Chemother; 2024 Feb; 36(1):31-34. PubMed ID: 37602423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.
    Moenster RP; Wallace-Lacey A; Western H; Tiefenaur S; Abdulbasir A; Alberts J; Doty J; Abner H; Skouby D; Lorenz M; Fong R; Arora J; Linneman TW
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad411. PubMed ID: 37937043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs.
    Ahiskali A; Rhodes H
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):73. PubMed ID: 33115540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
    Brade KD; Rybak JM; Rybak MJ
    Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.